Biotech & Health Tech
STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major test
Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.
Servier reports a surprise setback for a drug being tested for a form of muscular dystrophy that lacks treatment.
This is a summary of the story. Read the full article at Stat News (Biotech & Health Tech) ↗